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A B S T R A C T
Mast cells (MCs) have been reported to be one of the important immunoregulatory cells in promoting
the development of colitis-related colon cancer (CRC). It is not clear which MC subtypes play critical roles
in CRC progression from colitis to cancer because mucosal mast cells (MMCs) are distinct from connec-
tive tissuemast cells (CTMCs) inmaintaining intestinal barrier function under homeostatic and inﬂammatory
conditions. In the current study, we found that MMC numbers and the gene expressions of MMC-
speciﬁc proteases increased signiﬁcantly in an induced CRC murine model. The production of mast cell
protease-1 (mMCP-1) after MMC activation not only resulted in the accumulation of CD11b+Gr1+ inﬂam-
matory cells in the colon tissues but also modulated the activities of CD11b+Gr1+ cells to support tumor
cell growth and to inhibit T cell activation. Blocking the MMC activity in mice that had developed colitis-
related epithelium dysplasia, CD11b+Gr1+ inﬁltration was reduced and CRC development was inhibited.
Our results suggest that MMC activation recruited and modulated the CD11b+Gr1+ cells to promote CRC
and that MMCs can be potential therapeutic targets for the prevention of CRC development.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Intrinsic genetic lesions are critical in tumor formation; never-
theless, the importance of chronic inﬂammation in cancer develop-
ment has been highlighted recently [1–3]. MCs are abundant at sites
exposed to the external environment, such as the intestine, and con-
sidered to be important sentinel cells for the inﬂammatory stimuli.
Early studies demonstrated that these cells were vital in medicat-
ing bacterial clearance at the sites of infection by producing TNF-α
and recruiting neutrophils [4,5]. Their immunomodulatory func-
tions have been observed in a variety of inﬂammatory diseases,
including allergy and autoimmune diseases [6].
Innate and adaptive immune cells shape tumor growth [2,7]. The
roles of MCs in tumor development have attracted attention in recent
years. MC inﬁltration has been documented in several types of human
tumors. However, the role of MCs in the tumor microenvironment
is still debated [8–11]. The mechanisms that underline the oppo-
site effect of MCs on cancer are unclear.
Clinical and experimental animal studies suggest that an altered
intestinal epithelium creates a tumorigenic microenvironment that
boosts tumor progression [12,13]. In fact, different types of MCs are
distinct in maintaining the intestinal barrier function under ho-
meostatic and inﬂammatory conditions [14,15]. Two major MC
subtypes, MMCs and CTMCs, have been described so far [16,17]. The
MMCs mainly reside within the mucosa of the intestinal and re-
spiratory tracts and contain mouse mast cell protease (mMCP)-1
and mMCP-2 (chymases); they rarely express tryptase. The CTMCs
reside in the submucosa of the gastrointestinal tract and dermis and
express the chymases mMCP-4 and mMCP-5, and the tryptases
mMCP-6, mMCP-7, and carboxypeptidase A (CPA) [18,19]. Under ho-
meostatic conditions, the overall MC numbers are low, with an
approximate 1:1 ratio of MMCs to CTMCs. However, the ratio changed
to approximately 5:1 MMCs to CTMCs under inﬂammatory condi-
tions, with the numbers increased approximately 20–25-fold [20].
Consistent with the increased number of MMCs, remarkably in-
creasedmMCP-1 levels were observed [14]. In a colitis-related colon
(CRC) animal model, it was found that the mice lacking MCs were
less susceptible to inﬂammation-associated colorectal carcinogen-
esis [21]. However, it is unclear whichMC subtype is mainly involved
in the progression from colitis to cancer.
Abbreviations: CRC, colitis-related colon cancer; MC, mast cells; MMC, mucosal
mast cells; CTMC, connective tissue mast cells; mMCP, mouse mast cell protease;
DSS, dextran sodium sulfate; AOM, azoxymethane; DSCG, disodium cromoglycate.
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In this study, we reported that the activation of MMCs not only
resulted in the accumulation of CD11b+Gr1+ inﬂammatory cells in
the colon tissues but also modulated the activities of CD11b+Gr1+
cells to create a microenvironment for tumor growth. Blocking the
MMC activity in vivo at the stage of colitis-related epithelium dys-
plasia reduced CD11b+Gr1+ inﬁltration and inhibited CRC de-
velopment in the murine model.
Materials and methods
Mice
Male C57BL/6 or Balb/c mice, 8–10 weeks, were purchased from the Institute
of Laboratory Animal Sciences, Chinese Academy of Medical Sciences (CAMS, Beijing,
China). All procedures involving mice were approved by the Institutional Animal Care
and Use Committee at the Cancer Institute, CAMS.
CRC induction for analysis of mouse MC proteases
CRC was induced as reported [22]. Brieﬂy, azoxymethane (AOM; Sigma-
Aldrich, MO) was injected intraperitoneally at 12.5 mg/kg body weight. One week
later, the mice were exposed orally to 2.5% dextran sodium sulfate (DSS,
M.W. = 36,000–50,000 LLC, MP Biomedicals, OH) for 5 days, followed by a 16-day
fresh water interval. The continuous 21-day was designated as one DSS cycle. Animals
sacriﬁced at the end of the ﬁrst DSS cycle were designated as AD1, and those sac-
riﬁced at the end of cycles 2 and 3 were designated as AD2 and AD3, respectively.
At AD1, AD2, and AD3, four mice were sacriﬁced, the distal 2 cm colon or polyps
area were harvested for RNA isolation using Trizol reagent (Takara, Dalian, China).
As controls, four untreated mice were processed in the same way. Gene expression
array was carried out with a 4 × 44 K AgilentWhole Mouse Genome Oligo Microarray
Kit (G4122F). All data were normalized and analyzed with GeneSpring Software.
Colon tissues obtained from another independent experiment were processed
and analyzed individually by quantiﬁed real-time PCR to conﬁrm the ﬁndings in
transcriptome analysis. Primers used for quantitative PCR (Supplementary Table S1)
were GeneCopoeia All-in-One qPCR Primers purchased from FulenGen (Gua-
ngzhou, China). Relative expressions were calculated based on GAPDH.
Blocking MMC activation using MC stabilizers
Oral exposure to DSS induced acute colitis in mice [23,24]. To avoid the acute
effects of DSS on MC activation, we adopted a novel CRC animal model reported by
Tanaka et al. [25] to investigate the MMC in CRC development. Male C57BL/6 mice
received intraperitoneal AOM. One week later, they were exposed orally to 2.5% DSS
for 7 days. Then fresh water was replaced without further treatment. Eight weeks
after DSS withdrawal, we treated the mice with two MMC stabilizers, DSCG or
doxantrazole [26–28]. One group of mice (n = 10) received DSCG daily at 100 mg/
kg body weight dissolved in 100 μl saline for one week by gavage; one group (n = 10)
received doxantrazole daily by intraperitoneal injection at 5 mg/kg body weight dis-
solved in 100 μl 5% NaHCO3 for three days. The reagents were purchased from Sigma-
Aldrich. As controls, one group (n = 10) received 100 μl saline by gavage for one week;
one group (n = 10) was injected intraperitoneally with 100 μl 5% NaHCO3 for 3 days.
Mice were sacriﬁced 4 weeks after completing the treatment. Treatment experi-
ments were repeated twice.
Five mice at each of the following time points were sacriﬁced: 3 days, 3 weeks,
8 weeks, and 12 weeks after the DSS withdrawal. Each colon was opened longitu-
dinally and any fecal contents were cleared out with ice-cold saline. The colon length
and weight were measured, the numbers and sizes of polyps were macroscopi-
cally assessed individually.
Depleting CD11b+Gr1+ cells in vivo
We depleted the CD11b+Gr-1+ cells in vivo based on the report [29] using anti-
mouse Gr1 antibodies (RB6-8C5; eBioscience). Eight and nine weeks after DSS
withdrawal, each mouse received 200 μg RB6-8C5 antibody or rat IgG isotype in-
traperitoneally. Mice were sacriﬁced 4 weeks after completing treatment.
Flow cytometry analysis (FACS) of the inﬁltrated cells in the colon
When no tumor was macroscopically observed in longitudinally opened colons,
intraepithelial lymphocytes (IEL) and lamina propria lymphocytes (LPL) were iso-
lated as described [30].When tumorswere ready to be identiﬁed, the tumorous tissues
and tumor-adjacent tissues were collected separately and processed as performed
for LPL isolation. Digested tissues were ﬁltrated through a 100 μm pore size mesh
(BD Company, CA) to remove debris. Isolated cells were stained with FITC-conjugated
anti-mouse CD45, PE.Cy7-conjugated anti-mouse CD11b, and APC-conjugated anti-
mouse Gr1. Data were acquired in LSR-II (BD Company, CA) and analyzed by using
FlowJo software (Tree Start, OR). The analyses were based on the gating of CD45-
positive cells.
Staining MCs in colon tissues
MCs were stained as reported using toluidine blue [25]. The expressions of
mMCP-1 and mMCP-6 were stained using immunohistochemistry. Brieﬂy, sec-
tioned tissues were treated in PBS solution containing 1% Triton X-100 for 30 min
after antigens were retrieved in 0.01 M citrate buffer (pH = 6) to improve antigen
exposure. The section was then incubated with 50 μg/ml rat anti-mouse mMCP-1
monoclonal antibody (eBioscience, San Diego, CA), or with 1:500 diluted goat anti-
mouse mMCP-6 polyclonal antibodies (Santa Cruz, CA) in PBS solution containing
0.05% Tween-20 and normal rat and goat serum overnight at 4 °C. The same amount
of rat IgG or goat IgGwas used as an isotype control. For mMCP-1 staining, the section
was incubated with 1:500 diluted biotinylated goat anti-rat at room temperature
for 1 h, followed by HRP–avidin (ZSGB-Bio, Beijing, China) for 30 min. For mMCP-6
staining, the section was incubated with 1:50 diluted HRP-conjugated rabbit anti-
goat for 2 h. The sections were colored with 3-Amino-9-ethylcarbazole (AEC, Sigma,
MO) solution for 5–15 min and analyzed in Aperio Scanscope and Console soft-
ware version 10 (Aperio Technologies, Vista, CA).
Quantiﬁcation of mMCP-1 in serum and in colon tissues
To quantify the mMCP-1 in colon tissues, interstitial liquid was prepared as re-
ported [31]. Every 100-mg tissue sample was cut into small pieces in 400 μl ice-
cold normal saline and incubated on ice for 5 min. The mMCP-1 concentrations in
the interstitial liquid and in the serum were measured using mMCP-1 ELISA kits
(eBioscience, CA) according to the manufacturer’s instructions.
Assay of mMCP-1 on inﬂammatory cell recruitment in vivo
Themice received 10 ng recombinantmMCP-1 diluted into 0.5ml DMEMmedium,
or 0.5 ml DMEMmedium alone, intraperitoneally. Cells in peritoneal cavity were col-
lected and counted 22 h after the injection, stained with FITC-conjugated anti-
mouse CD45, PE-conjugated anti-mouse CD11b, APC-conjugated anti-mouse Gr1,
and PercpCy5.5-conjugated anti-mouse Ly6c. These assays were repeated four times.
Assays of CD11b+Gr1+ cell activity treated with recombinant mMCP-1
Inﬂammatory cells from Balb/c mice were collected from the peritoneal cavity
22 h after injecting 1 ml 4% thioglycollate (Sigma, St. Louis, MO) solution as in our
previous report [32]. CD11b+Gr1+ cells were sorted in FACSAria (BD Company, CA)
and cultured (5 × 105/ml) in DMEM containing 10% FBS in the presence or absence
of 10 ng/ml recombinant mMCP-1 for 48 h. Conditioned medium was collected to
determine its activity on colon cancer cell proliferation (CT26 cell line, Balb/c back-
ground). The treated CD11b+Gr1+ cells were used as stimulators on allogeneic (C57BL/6
background) T cell proliferation. The cell proliferation was determined using a CCK8
kit (Dojindo Lab, Japan) according to the manufacturer’s instructions. Experiments
were repeated three times.
Statistical analysis
All statistical analyses were performed using the GraphPad InStat 3 program (La
Jolla, CA). Student’s t-test or the Mann–Whitney U test was used for comparison
between groups. Results are expressed as themean ± SD ormedians with interquartile
range. Differences were considered to be statistically signiﬁcant for p < 0.05.
Results
MMCs and CTMCs in the tumor tissues
Animal colon adenoma was induced by the combination of AOM
and DSS exposures (Supplementary Fig. S1A). Histological analy-
sis showed the evolutionary process from inﬂammation to dysplasia
to adenoma in the mouse colon (Supplementary Fig. S1B). Consis-
tent with the other reports, the adenoma was mainly observed in
themiddle to distal colon at AD3. Transcriptome analysis of the colon
tissues demonstrated that the expression of genes encoding MC-
speciﬁc proteases increased dramatically in the mice with adenoma
compared with naive mice and with the mice with chronic inﬂam-
mation (Fig. 1A). The up-regulation of these genes in the colon tissues
was veriﬁed by real-time PCR (Supplementary Fig. S1C).
Compared with the mRNA expression of MC-speciﬁc proteases
in the adjacent non-tumor colon tissues, MMC-speciﬁc mMCP-1 and
mMCP-2 were the most highly upregulated in the tumor tissue
(Fig. 1B). We then investigated the MC numbers and their distri-
butions. In the colon tissues, MCs were rare in the naive mice.
However, MC numbers increased signiﬁcantly in the adenoma
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compared with the adjacent non-tumor tissues, mainly observed
within the epithelium (Fig. 1C-a, D).
To distinguish the subtypes of increased MCs, we stained the
tumor and tumor-adjacent tissues with antibody against mMCP-1
(Fig. 1C-b), which is speciﬁcally expressed by MMCs, or with anti-
body against mMCP-6 (Fig. 1C-c), which is speciﬁcally expressed by
CTMCs. BothmMCP-1-positive cells andmMCP-6-positive cells were
higher in the tumor tissues than in tumor-adjacent tissues. However,
more mMCP-1-positive MMCs than mMCP-6-positive CTMCs were
observed in the tumor tissues, but not in the non-tumor tissues
(Fig. 1E).
MMCs were activated during CRC development
The mice with adenoma (AD3) had signiﬁcantly increased serum
mMCP-1, the MMC-speciﬁc product, averaging 14.3 ± 1.3 ng/ml, than
the naive mice (0.5 ± 0.1 ng/ml). We then processed the tissues and
collected interstitial liquid. The mMCP-1 in tumors was 47.8 ± 7.5 ng
per 100 mg tissues, which was signiﬁcantly higher than that in the
colon of naive mice (2.1 ± 0.4 ng/100 mg tissues).
Oral exposure to DSS might activate MMC directly. We there-
fore adopted the novel CRC animal model [25] (Fig. 2A) to investigate
the role of MMC in CRC development. Histology analysis demon-
strated that inﬂammatory cell inﬁltration was obvious 3 days after
DSS withdrawal and was still remarkable 3 weeks after that
(Fig. 2B-a). Epithelium dysplasia was observed after 8 weeks
(Fig. 2B-b) and all of the mice developed colon tumors 12 weeks
after DSS withdrawal in the middle to distal colon (Fig. 2B-c).
Compared with the naive mice, serummMCP-1 increased grad-
ually 3 weeks, 8 weeks and 12 weeks after DSS withdrawal, but no
changes were seen after AOM and 3 days after DSS withdrawal
(Fig. 2C). In colon tissue, the mMCP-1 showed the same pattern as
in the serum. However, 3 days after DSS withdrawal, the mMCP-1
levels in colon tissue increased signiﬁcantly relative to that of the
naive mice (Fig. 2D). These results suggest that MMCs might be an
important player in CRC development.
Fig. 1. MMCs and CTMCs in murine CRC induced by AOM + DSS. (A) Relative expression of mast cell-speciﬁc proteases by microarray determined at different time points.
Colon tissues collected at the end of the ﬁrst DSS cycle were assigned as group AD1, and those collected at the end of cycles 2 and 3 were AD2 and AD3, respectively. Un-
treated mice (Naive) were used as the baseline expression. (B) Expression of MMC-speciﬁc mMCP-1, mMCP-2 and CTMC-speciﬁc mMCP-4, CPA in the tumors (ﬁlled bars)
and tumor-adjacent tissues (empty bars). The colon tissues collected from naive mice were used as control (gray bars). (C) Representative images of mast cells in tumor
tissue: (a) mast cells stained by toluidine blue (purplish blue-staining); (b) mMCP-1 speciﬁc MMCs and (c) mMCP-6 speciﬁc CTMCs stained by immunohistochemistry (red-
staining). (D) Numbers of total mast cells, (E) mMCP-1 speciﬁc MMCs, mMCP-6 speciﬁc CTMCs were quantiﬁed under microscope in tumor or tumor-adjacent tissues (No-
tumor). Each dot represents the average of 3 sections from one mouse. Five untreated mice with the same weeks were used as control (Naive). (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Blockade of MMC activation inhibited CRC development
We treated the mice with DSCG or with doxantrazole to vali-
dateMMCs’ roles in CRC development (Fig. 3A). The drugs were given
at 8 weeks after DSS withdrawal, when the mice developed low-
grade epithelium dysplasia (LGD) with chronic inﬂammation in their
colon tissues (as shown in Fig. 2B-b). In controls, themice were sham
treated with saline or with NaHCO3 (Fig. 3A).
The mice treated with either DSCG or with doxantrazole had a
smaller colon weight than the sham-treated mice (P < 0.05,
Supplementary Fig. S2). Total tumor numbers and those greater than
4 mm in diameter decreased signiﬁcantly in the drug-treated rel-
ative to the sham-treated mice (Fig. 3B). In parallel, mMCP-1 levels
in serum (Fig. 3C) and in the interstitial liquid of colon tissues
(Fig. 3D) were reduced signiﬁcantly in the drug-treated relative to
the sham-treatedmice. These results suggest that blockade of MMCs’
activity could decrease CRC development in the murine model.
MMC activation resulted in CD11b+Gr-1+ cell accumulation during
CRC development
Massive inﬁltration of inﬂammatory cells was observed in the
adenoma tissues. There was a positive correlation between CD45+
inﬂammatory cell numbers and tissue mMCP-1 levels in the colon
(P = 0.03, Fig. 4A). Phenotype analysis demonstrated that more than
70% of CD45+ cells were CD11b+Gr1+ in the tumor tissues, while it
was less than 50% in the tumor adjacent tissues (Fig. 4B). We then
analyzed this population at different stages during CRC develop-
ment. Compared with acute colitis (3 days after DSS withdrawal),
more CD11b+Gr1+ cells were observed in the epithelium, but not in
the lamina propria at the stage of chronic colitis (3 weeks after the
DSSwithdrawal). Notably, more CD11b+Gr1+ cells presented in stages
of dysplasia (8 weeks after the DSS withdrawal) and in the tumors,
most prominently in the epithelium (Fig. 4C and Supplementary
Fig. S3). After the mice were treated with MC stabilizers, paralleled
Fig. 2. Production of MMC-speciﬁc mMCP-1 during the course of CRC development. (A) Diagram of the adopted novel CRC animal model induced based on Ref. 25.
(B) Representatives of the colon tissues examined 3 weeks (a), 8 weeks (b), and 12 weeks after DSS withdrawal. (C) Serum levels; (D) tissue levels of mMCP-1 determined
at different time points after AOM injection or after DSS withdrawal. Each column represents the average of 3 individual mice at each time point. *: P < 0.05; **: P < 0.01.
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Fig. 3. Blocking MMC activity on CRC development in murine model. (A) Diagram of the treatment in the mice when they developed low grade dysplasia (LGD) induced by
AOM + DSS. Each group contained 10 mice. (B) Tumor numbers in different sizes, (C) mMCP-1 levels in serum, and (D) in colon tissues of the drug or sham-treated mice.
**: P < 0.01.
Fig. 4. Inﬁltration of CD11b+Gr1+ cells in the colon tissues. (A) Correlation of numbers of inﬁltrated inﬂammatory cells and mMCP-1 levels in the colon tissues. (B) Repre-
sentative of the CD11b+Gr1+ cells in tumor and tumor-adjacent (No-Tumor) tissues. C) Percentage of CD11b+Gr1+ cells in epithelium (intraepithelial lymphocytes, IEL) or in
lamina propria (lamina propria lymphocytes, LPL) at different time points after DSS withdrawal. Calculation of the CD11b+Gr1+ cell percentage was based on CD45+ cells. D)
Percentage of CD11b+Gr1+ cells in the tumor tissues of sham (Saline) or DSCG treated mice. (E) Representative of these mice. Five untreated mice with the same weeks
were used as control (Naive).
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with reducedmMCP-1 levels (Fig. 3D), the percentage of CD11b+Gr1+
cells decreased signiﬁcantly in the colon tissues (Fig. 4D, E).
To conﬁrm the effect of activated MMC on the accumulation of
CD11b+Gr1+ cells, we injected recombinantmMCP-1 intomouse peri-
toneal cavity, where no MMCs reside. Inﬂammatory cell numbers
increased in the mice that received 10 ngmMCP-1 (Fig. 5A). Notably,
the CD11b+Gr1+ cells but not CD11b+Gr1− cells increased signiﬁ-
cantly in the mice that received mMCP-1 (Fig. 5B). In comparison
with the mice that received medium alone, the percentage of
CD11b+Gr1+Ly6chigh subpopulation increased in the mice that re-
ceived mMCP-1, similar to that in the mice that received thio-
glycollate (Fig. 5C). However, when we sorted the CD11b+Gr1+ cells
for chemotaxis assays, no direct effect of mMCP-1 on these cells was
observed in vitro (Supplementary Fig. S4).
CD11b+Gr1+ cells treated with mMCP-1 enhance tumor cell
proliferation and inhibit T cell activation
We then cultured the CD11b+Gr1+ cells with or without mMCP-1
to determine the effect of mMCP-1 alone, CD11b+Gr1+ cells alone,
and the mMCP-1-treated CD11b+Gr1+ cells on colon tumor cell pro-
liferation and on allogeneic T cell activation. The CT26 cell pro-
liferation showed no change when they were treated with the
medium collected from CD11b+Gr1+ cells alone or with mMCP-1
alone. However, CT26 cell proliferation increased signiﬁcantly with
conditioned medium from mMCP-1 treated CD11b+Gr1+ cells
(Fig. 6A). On the contrary, allogeneic T cell proliferation stimu-
lated by mMCP-1-treated CD11b+Gr1+ cells was inhibited compared
with that by CD11b+Gr1+ cells alone (Fig. 6B).
Removing CD11b+Gr1+ cells inhibited CRC development
The above results suggest that activation of MMCs modulated
CD11b+Gr1+ cell activity, which enhanced the tumor cell proliferation
and inhibited the T cell activity that promoted CRC development.
We then depleted CD11b+Gr1+ cells in the mice that had devel-
oped dysplasia by injecting anti-Gr1 antibody. Four weeks after the
antibody treatment, the tumor numbers in the anti-Gr1 antibody-
treatedmice decreased signiﬁcantly comparedwith themice treated
with isotype control (Fig. 6C).
Discussion
In this study we found that MC numbers and MC-speciﬁc pro-
tease expressions increased signiﬁcantly in tumors compared with
the adjacent non-tumor tissues. Notably, more mMCP1-positive
MMCs than mMCP6-positive CTMCs were observed in tumor but
not in tumor-adjacent tissues. Signiﬁcantly increased mMCP-1 was
determined in tumors. Blocking the activities of MMCs, mMCP-1
levels both in serum and in colon tissues decreased, inﬁltration of
CD11b+Gr1+ cells was alleviated, and the tumor numbers were
reduced. After administration of recombinant mMCP-1 in vivo the
numbers of CD11b+Gr1+ but not CD11b+Gr1− cells increased signiﬁ-
cantly. ThemMCP-1 conditionedmedium from CD11b+Gr1+ cells but
Fig. 5. Effect of recombinant mMCP-1 on CD11b+Gr1+ cell recruitment in vivo. Balb/C
mice either received 0.5 ml DMEM medium alone (n = 8) or the same volume con-
taining 10 ng mMCP-1 (n = 12). Twenty hours after the injection, cells inﬁltrated into
the peritoneal cavity were collected using 5 ml of DMEMmedium. (A) The total cell
numbers, (B) the numbers of CD11b+Gr1+ cells or CD11b+Gr1− cells in each group
of the mice with FACS staining in different treated group. (C) Expression of Ly6c in
the CD11b+Gr1+ cells. The mice received 1ml of 4% thiogylcollate was used as control.
Fig. 6. Effect of recombinant mMCP-1 on CD11b+Gr1+ cell activity. The sorted
CD11b+Gr1+ cells (at concentration of 5 × 105/ml) were cultured in the presence or
absence of mMCP-1. Parallel, mMCP-1 was included in the medium without cells
included (diagram provided in Supplementary Fig. S5). (A) The conditioned medium
was collected and diluted with normal culture medium at 1:1 ration. Colon cancer
cell line, CT 26 cells (at the concentration of 5 × 104/ml), were cultured in the pres-
ence of the above collected medium for another 48 hours and the cell proliferation
was determined by using CCK8 kit. (B) Allogeneic (C57BL/6 background) T cells were
prepared and mixed with the above cells for 68 hours at the ratio of one CD11b+Gr1+
cell to two T cells. The T cell proliferation was determined by using CCK8 kit. The
cell proliferation was quantiﬁed by determining the absorbance at OD450nm. Ex-
periments were repeated 3 times. (C) The mice were treated with rat anti-murine
Gr1 antibodies or rat IgG (each group contained 5 mice). The mice were then sac-
riﬁced 4 weeks after the antibody treatment was completed.
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not the medium from CD11b+Gr1+ cells alone or mMCP-1 alone was
able to support colon cancer cell proliferation. In addition, alloge-
neic T-cell proliferation stimulated by mMCP-1-treated CD11b+Gr1+
cells was inhibited compared with that by CD11b+Gr1+ cells alone.
Removing the CD11b+Gr1+ cells without affecting the MMCs in mice
the tumor growth was inhibited. These data demonstrated that
MMCs are important players in CRC development, whichmightmod-
ulate the CD11b+Gr1+ cell activity in the inﬂamed colon tissues.
It was found that there was a large pool of MC progenitors in
murine small intestine and the establishment of MC progenitor res-
ervoir depended on the α4β7 integrin expressions. MMC hyperplasia
associated with Trichinella spiralis infection in small intestine was
proposed due to the established MC progenitor reservoir [33].
Whether the increase of MMCs during CRC development in the
murine model was related to the small intestine reservoir and the
involvement of integrins needs to be addressed in the future.
The way of inﬂammatory cells and their products in affecting the
tumor development has been explored [1]. It remains largely
unknown how these cells are accumulated in promoting the CRC
development. MCs are abundant at sites exposed to the external en-
vironment, such as the intestine [6]. MMCs and CTMCs were found
to have different functions in the intestine [14,15]. The distinction
between MMCs and CTMCs is acquired during the local tissue de-
velopment of the subsets rather than being ﬁxed either by the genetic
makeup of their progenitors or their classical location [33]. Previ-
ously, we found that degranulation of skin MCs (CTMC subtype)
boosted the homing of monocyte-derived dendritic cells [34]. MMCs
were found different in their proteases and their production of
eicosanoids and the other mediators after activation [33]. In our
current study, we found a positive correlation between CD45+ in-
ﬂammatory cell numbers and tissue mMCP-1 levels in the colon.
More than 70% of CD45+ cells were CD11b+Gr1+ in the tumor tissues,
while this value was less than 50% in the tumor-adjacent tissues.
MMC products seemed important in mobilizing inﬂammatory
CD11b+Gr1+ cells during CRC development. However, the effect of
mMCP-1 might be indirect as no chemotaxis of mMCP-1 on these
cells was observed. The cleavage activity of mMCP-1 on speciﬁed
amino acids of some proteins has been documented and base-
mentmembrane proteins and cell adhesion proteins were considered
to be highly interesting potential substrates for mMCP-1 [35]. Our
current study suggests that the activation of MMCs induced
CD11b+Gr1+ cell accumulation in the inﬂamed colon tissues prob-
ably by impairing the barrier function of intestinal mucosa.However,
we cannot exclude the effect of luminal bacteria translocation after
the MMC activation, which in turn regulates the inﬁltrated cell func-
tion to boost tumor development.
An altered intestinal epithelium creates a favorable tumorigen-
ic microenvironment [12] and the microbe and the microbial
products within themucosa cause the activation of the immune cells,
which in turn drives the tumor growth [13]. The roles of MCs in pro-
moting tumor development were recently observed [19,21,36].
During our manuscript preparation, Pucillo and colleagues re-
ported that MCs boost the activity of myeloid-derived suppressor
cells, the heterogeneous cells with the phenotypes of CD11b+Gr1+
expression, and contribute to the development of the tumor-
favoring microenvironment [37]. However, it is unclear which
subtype of theMCs plays critical roles in tumor initiation or becomes
involved in the progression from colitis to cancer [21,36]. Our current
study demonstrated that the activation of MMCs not only re-
cruited the CD11b+Gr1+ cells but also modulated the cell activity to
promote CRC development. Some soluble factors from mMCP-1-
treated CD11b+Gr1+ cells supported colon cancer cell proliferation.
In addition, T cell activation was also inhibited when the CD11b+Gr1+
cells were treated by mMCP-1. Therefore, a favorable cancer-
promoting inﬂammatory microenvironment was created in the
presence/activation of MMCs. Indeed, some other studies suggested
that MCs regulate both innate and adaptive immunity throughmany
types of release mediators after activation, such as histamine [38],
turning the immune responses toward tumor progression [16].
Inhibition of MC activity with a therapeutic purpose has been
widely exploited using histamine antagonists against allergic re-
actions. In recent decades, many new targets of MCs have been
identiﬁed, offering new therapeutic opportunities for numerous in-
ﬂammatory diseases and perhaps for cancers [16]. Our current study
provided data on the prevention of CRC development by blocking
MMC activity using current clinically used drugs. MCs can serve as
potential therapeutic targets for preventing CRC development.
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